However, it is important to note that despite the results in many studies, preclinical investigations showed that the combination of 177Lu-PSMA with different PARPi, including veliparib, olaparib, and talazoparib, did not result in a synergistic antitumor effect in PCa [188]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.